X = Y(A - B) ------- APTC Therapeutics, Inc. • March 31st, 2006 • Delaware
Company FiledMarch 31st, 2006 Jurisdiction
WARRANTPTC Therapeutics, Inc. • March 31st, 2006 • New York
Company FiledMarch 31st, 2006 Jurisdiction
Underwriting AgreementPTC Therapeutics, Inc. • January 25th, 2019 • Pharmaceutical preparations • New York
Company FiledJanuary 25th, 2019 Industry JurisdictionPTC Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 6,720,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,008,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.
PTC THERAPEUTICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 20, 2019Indenture • September 20th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 20th, 2019 Company Industry JurisdictionINDENTURE dated as of September 20, 2019 between PTC THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
PTC THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) At the Market Offering Sales AgreementSales Agreement • August 7th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2019 Company Industry JurisdictionPTC Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an “Agent,” and collectively, the “Agents”), as follows:
Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE...PTC Therapeutics, Inc. • March 31st, 2006 • New Jersey
Company FiledMarch 31st, 2006 Jurisdiction
PTC THERAPEUTICS, INC. 2,475,248 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 20th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 20th, 2019 Company Industry JurisdictionPTC Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 2,475,248 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 371,287 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Underwritten Shares and the Option Shares, to the extent issued, are referred to herein as the “Stock”. To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.
X = Y (A - B) --------- APTC Therapeutics, Inc. • March 31st, 2006 • Delaware
Company FiledMarch 31st, 2006 Jurisdiction
Exhibit 10.5 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT dated as of March 17, 2006 by and between PTC THERAPEUTICS, INC.Collaboration and License Agreement • March 31st, 2006 • PTC Therapeutics, Inc. • New York
Contract Type FiledMarch 31st, 2006 Company Jurisdiction
CREDIT AND SECURITY AGREEMENT dated as of May 5, 2017 by and among PTC THERAPEUTICS, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a...Credit and Security Agreement • May 8th, 2017 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 8th, 2017 Company Industry JurisdictionThis CREDIT AND SECURITY AGREEMENT (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of May 5, 2017 by and among PTC THERAPEUTICS, INC., a Delaware corporation (“PTC”), and any additional borrower that may hereafter be added to this Agreement (individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender.
MASTER SECURITY AGREEMENT NO. 4081064 Dated as of JULY 30, 2004 ("AGREEMENT")Master Security Agreement • March 31st, 2006 • PTC Therapeutics, Inc. • Virginia
Contract Type FiledMarch 31st, 2006 Company Jurisdiction
EMPLOYMENT AGREEMENTEmployment Agreement • April 25th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledApril 25th, 2024 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is made as of May 4, 2020 (the “Effective Date”), by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”) and Lee Golden (“Executive”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows:
EXHIBIT 4.2 FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this "Agreement") made as of September 21, 2005 (the "Effective Date") by and among (i) PTC Therapeutics, Inc., a Delaware...Investor Rights Agreement • March 31st, 2006 • PTC Therapeutics, Inc. • Delaware
Contract Type FiledMarch 31st, 2006 Company Jurisdiction
PTC Therapeutics, Inc. Restricted Stock Agreement Granted Under 2013 Stock Incentive PlanRestricted Stock Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 16th, 2013 Company Industry Jurisdiction
PTC Therapeutics, Inc. Nonstatutory Stock Option AgreementNonstatutory Stock Option Agreement • March 5th, 2014 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 5th, 2014 Company Industry Jurisdiction
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CREDIT AGREEMENT dated...Credit Agreement • September 22nd, 2023 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 22nd, 2023 Company Industry JurisdictionThis CREDIT AGREEMENT is entered into as of October 27, 2022, among PTC THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Guarantors (as defined herein) from time to time party hereto, the Lenders (as defined herein) from time to time party hereto and Wilmington Trust, National Association, as Administrative Agent (as defined herein).
PTC Therapeutics, Inc. Restricted Stock Unit AgreementRestricted Stock Unit Agreement • February 21st, 2023 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 21st, 2023 Company Industry JurisdictionPTC Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its Amended and Restated 2013 Long-Term Incentive Plan. The terms and conditions attached hereto are also a part hereof.
EMPLOYMENT AGREEMENTEmployment Agreement • July 17th, 2023 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledJuly 17th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 13, 2023 (the “Effective Date”), by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”) and Pierre Gravier (as more fully specified in Schedule 1.1, “Executive”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows:
PTC Therapeutics, Inc. Incentive Stock Option Agreement Granted Under Amended and Restated 2013 Long-Term Incentive PlanIncentive Stock Option Agreement • February 21st, 2023 • PTC Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 21st, 2023 Company IndustryThis agreement evidences the grant by PTC Therapeutics, Inc., a Delaware corporation (the “Company”), on [Grant Date] (the “Grant Date”) to [Participant Name], an employee of the Company (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s Amended and Restated 2013 Long-Term Incentive Plan (the “Plan”), a total of [Number of Awards Granted] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (“Common Stock”) at $[Grant Price] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on [Expiration Date] (the “Final Exercise Date”).
AGREEMENT FOR THE PROVISION OF FUNDING TO PTC THERAPEUTICS, INC. FOR RESEARCH RELATING TO SELECTIVELY DECREASING THE PRODUCTION OF BMI-1 EXPRESSION IN TUMOUR STEM CELLSAgreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • England
Contract Type FiledMay 16th, 2013 Company Industry Jurisdiction
EXHIBIT 10.14 PROMISSORY NOTE TO MASTER SECURITY AGREEMENT NO. _________Master Security Agreement • March 31st, 2006 • PTC Therapeutics, Inc. • Virginia
Contract Type FiledMarch 31st, 2006 Company JurisdictionFOR VALUE RECEIVED, PTC Therapeutics, Inc., a Delaware corporation, located at the address stated below ("MAKER") promises, jointly and severally if more than one, to pay to the order of OXFORD FINANCE CORPORATION or any subsequent holder hereof (each, a "PAYEE") at its office located at 133 N. FAIRFAX STREET, ALEXANDRIA, VA 22314 or at such other place as Payee or the holder hereof may designate, the principal sum of ____________________ DOLLARS ($____________________), with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of ______ and _____ hundredths percent (____%) per annum, in ________ consecutive monthly installments of principal and interest as follows:
AGREEMENT FOR THE PROVISION OF FUNDING TO PTC THERAPEUTICS, INC. FOR RESEARCH RELATING TO THE LEAD OPTIMISATION AND DEVELOPMENT OF NOVEL BACTERIAL DNA SYNTHESIS INHIBITORS FOR THE TREATMENT OF NOSOCOMIAL INFECTIONS CAUSED BY MULTI-DRUG RESISTANT...Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • England
Contract Type FiledMay 16th, 2013 Company Industry Jurisdiction
AMENDMENT NO. 1 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • July 19th, 2018 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 19th, 2018 Company Industry JurisdictionThis AMENDMENT NO. 1 AND LIMITED CONSENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 19th day of July, 2018, by and among PTC Therapeutics, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
Exhibit 10.12 Table of Contents TABLE OF CONTENTS OF LEASE BETWEEN 46.24 ASSOCIATES L.P., AS LANDLORD, AND PTC THERAPEUTICS, INC., AS TENANT, FOR PREMISES LOCATED IN 100 CORPORATE COURT, MIDDLESEX BUSINESS CENTER, SOUTH PLAINFIELD, NEW JERSEYAnd Attornment Agreement • March 31st, 2006 • PTC Therapeutics, Inc. • New Jersey
Contract Type FiledMarch 31st, 2006 Company Jurisdiction
PTC Therapeutics, Inc. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive PlanNonstatutory Stock Option Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMay 16th, 2013 Company Industry
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Royalty Purchase Agreement • February 29th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 29th, 2024 Company Industry JurisdictionThis AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT, dated as of October 18, 2023 (this “Agreement”), is made and entered into by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), and, solely for the purposes of Section 5.15 hereof, Royalty Pharma plc, a limited company organized under the laws of England and Wales.
PTC THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Dated as of March 7, 2013Rights Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 16th, 2013 Company Industry JurisdictionTHIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT, is entered into as of March 7, 2013 (this “Agreement”), among PTC THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A and Schedule B hereto (each of which is referred to in this Agreement as an “Investor”).
AMENDMENT NO.2 TO CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • October 30th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 30th, 2019 Company Industry JurisdictionThis AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 7th day of August, 2019, by and among PTC Therapeutics, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.
LOAN AND SECURITY AGREEMENTLoan Modification Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 16th, 2013 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of September 21, 2009 (the “Effective Date”) among OXFORD FINANCE CORPORATION, a Delaware corporation with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (“Collateral Agent”), the Lenders listed on Schedule 1.1 hereof and otherwise party hereto from time to time (each a “Lender” and collectively, the “Lenders”), and PTC THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Lenders shall lend to Borrower and Borrower shall repay Lenders. The parties agree as follows:
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. License and Collaboration AgreementLicense and Collaboration Agreement • May 16th, 2013 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 16th, 2013 Company Industry JurisdictionWHEREAS, PTC has discovered proprietary compounds that are potentially useful for the treatment of spinal muscular atrophy and possesses proprietary technology and intellectual property rights relating thereto; and
ASSET PURCHASE AGREEMENT by and between PTC Therapeutics, Inc. as Buyer and BioElectron Technology Corporation, as Seller Dated as of October 1, 2019 THIS DOCUMENT IS NOT INTENDED TO CREATE NOR WILL IT BE DEEMED TO CREATE A LEGALLY BINDING OR...Asset Purchase Agreement • October 30th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 30th, 2019 Company Industry JurisdictionTHIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 1, 2019, by and between PTC Therapeutics, Inc., a Delaware corporation (“Buyer”), and BioElectron Technology Corporation, a Delaware corporation (“Seller”). Buyer and Seller may be referred to herein, together, as the “Parties” and, individually, as a “Party.”
LEASE AGREEMENT BRISTOL-MYERS SQUIBB COMPANY (LANDLORD) TO PTC THERAPEUTICS, INC. (TENANT) Effective Date: August 3, 2019Lease Agreement • October 30th, 2019 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledOctober 30th, 2019 Company Industry Jurisdiction
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SPONSORED RESEARCH...Sponsored Research Agreement • April 27th, 2023 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 27th, 2023 Company Industry JurisdictionThis third amendment (“Third Amendment”) to the Sponsored Research Agreement is effective as of the 1st day of January, 2011 (the “Third Amendment Effective Date”), by and between Spinal Muscular Atrophy Foundation (the “Foundation”) and PTC Therapeutics, Inc. (the “Company”), with reference to the following facts and circumstances.
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • March 2nd, 2020 • PTC Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 2nd, 2020 Company IndustryThis First Amendment (“First Amendment”) to the Lease Agreement ( “Lease”) is made on this 7th day of October 2019 by and between BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation, having an office at 3551 Lawrenceville Princeton Road, Princeton, New Jersey 08540 (“Landlord”), and PTC THERAPEUTICS, INC., a Delaware Corporation, having an office at 100 Corporate Court, South Plainfield, NJ 07080-2449 (“Tenant”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 1 TO...Royalty Purchase Agreement • August 8th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 8th, 2024 Company Industry JurisdictionThis AMENDMENT NO. 1 to the AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT dated as of October 18, 2023 (the “Purchase Agreement”) and FIRST PUT OPTION EXERCISE AGREEMENT (“Amendment No. 1”), is entered into on this 17th day of June, 2024, by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”) and Royalty Pharma plc, a public limited company established under the laws of England and Wales. Capitalized terms not defined herein have the meanings assigned to them in the Purchase Agreement.